1
|
Hsiao HH, Liu YC, Wang HC, Tsai YF, Wu CH, Cho SF, Hsu JF, Huang CT, Hsiao SY, Lee CP, Chang CS, Lin SF, Liu TC. Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. Genet Mol Res 2015; 14:17028-33. [PMID: 26681050 DOI: 10.4238/2015.december.16.3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Despite sharing a similar genetic abnormality, patients with core binding factor acute myeloid leukemia (CBF-AML), which is characterized by the presence of t(8;21) or inv(16)/t(16;16), show heterogeneous survival. Other molecular or cytogenetic factors are supposed to have an impact on the prognosis. We enrolled 24 CBF-AML patients to determine the impact of cytogenetic abnormality, and c-KIT, FLT3, NPM1, and CEBPA mutations on the prognosis. Only three patients had the c-KIT mutation (3/24, 12.5%) and one had the FLT3 mutation. However, over half of the patients (14/24) harbored additional cytogenetic changes, including ten with loss of sexual chromosomes (LOS) [all in the t(8;21) group], and six had additional abnormalities (two cases had both LOS and additional abnormalities). From this small-number study, no association was found between c-KIT mutation and survival and relapse rate. However, additional chromosome abnormalities had a significant association with relapse of the disease (P = 0.027). Stem cell transplant had a trend of benefitting patients after relapse (P = 0.065). This implies that chromosome abnormalities occur in CBF-AML and might take part in the heterogeneous nature of CBF-AML.
Collapse
Affiliation(s)
- H H Hsiao
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan.,Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.,Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Y C Liu
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan.,Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | - H C Wang
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - Y F Tsai
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - C H Wu
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - S F Cho
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - J F Hsu
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - C T Huang
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - S Y Hsiao
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - C P Lee
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan
| | - C S Chang
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan.,Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - S F Lin
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan.,Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - T C Liu
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan.,Department of Laboratory Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.,Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| |
Collapse
|
2
|
Liu YC, Hsiao HH, Lin PM, Yang WC, Chang CS, Liu TC, Hsu JF, Yang MY, Lin SF. Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. Genet Mol Res 2013; 12:5414-23. [PMID: 24301914 DOI: 10.4238/2013.november.11.3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Different molecular aberrations can be discriminated into certain prognostic subgroups in cytogenetically normal acute myeloid leukemia (CN-AML) patients but their impact on allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial and studies from Asian populations are lacking. Forty-two adult non-M3 AML patients receiving allo-HSCT from 2002 to 2009 in southern Taiwan were retrospectively reviewed for survey, 23 (54.7%) of whom were CN-AML. NPM1, FLT3-ITD, and CEBPA were analyzed. After a median follow-up of 104 weeks (range, 8 to 384), patients in the good risk group (harboring either NPM1 or CEBPA mutation without concurrent FLT3-ITD) showed a borderline worse overall survival (OS) compared with the intermediate/poor risk group (P = 0.08). Interestingly, a poorer OS was found in patients with the CEBPA mutation (P = 0.003) but not the NPM1 mutation (P = 0.96). No OS difference was found between patients with or without FLT3-ITD (P = 0.15). In patients receiving allo-HSCT at first remission, there was no significant OS benefit in the good risk group (P = 0.33). In patients receiving allo-HSCT beyond first remission, disease status played a major role (P = 0.006), irrespective of molecular aberrations. Allo-HSCT in good risk patients should be carefully evaluated in Taiwanese, especially in patients with the CEBPA mutation. Conversely, allo-HSCT should be considered in first remission in patients with an intermediate/poor risk, where it may overcome the adverse impact of FLT3-ITD. Disease status remained a main issue in patients receiving allo-HSCT beyond first remission.
Collapse
Affiliation(s)
- Y C Liu
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Hsiao HH, Liu YC, Hou MF, Lin SF. Uterine leiomyosarcoma metastasis to the breast. EUR J GYNAECOL ONCOL 2008; 29:191-192. [PMID: 18459564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND Uterine leiomyosarcoma is a rare female neoplasm with a high recurrent and metastatic rate. However, only a few cases have been reported on metastasis to the breast. The purpose of this work is to stress the role of follow-up and to increase physicians' awareness of such lesion. case: A 62-year-old female suffered from a breast nodule and multiple metastases six years after resection for uterine leiomyosarcoma. Pathology revealed a rare condition of uterine leiomyosarcoma with breast metastasis. CONCLUSION The case highlights the important role of long-term follow-up in uterine leiomyosarcoma and implies the necessity of tissue proof in patients with the disease.
Collapse
Affiliation(s)
- H H Hsiao
- Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
| | | | | | | |
Collapse
|
5
|
Hsiao HH, Liu TC, Chang CS, Sue YC, Chen TP, Lin SF. Secondary chronic myelogenous leukemia after autologous peripheral blood stem cell transplantation for Lymphoma. Int J Hematol 2001; 73:126-8. [PMID: 11372749 DOI: 10.1007/bf02981915] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A 31-year-old woman was diagnosed with intestinal lymphoma (high-grade mucosa-associated lymphoid tissue lymphoma, stage IIE) in September 1996. Eleven courses of chemotherapy were administered, but the results were poor. She received autologous peripheral blood stem cell transplantation (PBSCT) in September 1997. Leukocytosis was noted, and chronic myelogenous leukemia was diagnosed 8 months after the PBSCT, progressing to blast phase 10 months later. We report this case because secondary chronic myelogenous leukemia after stem cell transplantation is rare.
Collapse
MESH Headings
- Adult
- Antineoplastic Agents/administration & dosage
- Female
- Hematopoietic Stem Cell Transplantation/adverse effects
- Humans
- Intestinal Neoplasms/pathology
- Intestinal Neoplasms/therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Lymphoma, B-Cell, Marginal Zone/pathology
- Lymphoma, B-Cell, Marginal Zone/therapy
- Neoplasms, Second Primary/etiology
- Neoplasms, Second Primary/pathology
- Transplantation, Autologous/adverse effects
Collapse
Affiliation(s)
- H H Hsiao
- Department of Internal Medicine, Kaohsiung Medical University Hospital, Taiwan
| | | | | | | | | | | |
Collapse
|